Parents sue for daughter to use medical marijuana

An 11-year-old girl with leukemia suffers seizures due to years of chemotherapy. Her parents are suing the Chicago school district for banning her use of medical marijuana.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news

Related Links:

Conditions:   Recurrent B Acute Lymphoblastic Leukemia;   Recurrent T Acute Lymphoblastic Leukemia;   Refractory B Acute Lymphoblastic Leukemia;   Refractory T Acute Lymphoblastic Leukemia Interventions:   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Methotrexate;   Drug: Nelarabine;   Drug: Pegaspargase;   Drug: Prednisone;   Biological: Rituximab;   Drug: Venetoclax;   Drug: Vincristine Sponsors...
Source: - Category: Research Source Type: clinical trials
ConclusionThe present investigation showed that ungeremine is a promising cytotoxic compoundthat could be further explored in the future to develop new anticancer drugs to fight sensitive and resistant phenotypes.Graphical abstractUngeremine had cytotoxic effects on a panel of 9 cancer cell lines including dug-sensitive and multidrug-resistant phenotypes, with IC50 values below 75.24 µM. This compound induced ferroptosis, necroptosis, autophagy in CCRF-CEM leukemia cells, as well as apoptosis mediated by caspase activation, MMP alteration and increase ROS production.
Source: Phytomedicine - Category: Drugs & Pharmacology Source Type: research
Rhiannon Lindley, 27, of Springfield, Missouri, was diagnosed with leukemia in January 2018. As she undergoes chemotherapy, she is asking for breast milk donations for her daughter, Adelaide.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Treatment of acute leukemia is challenging and long-lasting remissions are difficult to induce. Innovative therapy approaches aim to complement standard chemotherapy to improve drug efficacy and decrease toxic...
Source: Cell Communication and Signaling - Category: Molecular Biology Authors: Tags: Research Source Type: research
Conditions:   Large-B-cell Diffuse Lymphoma;   Chronic Lymphoid Leukemia Interventions:   Drug: Rituximab;   Drug: Chemotherapy;   Drug: Tenofovir alafenamide Sponsor:   Gruppo Italiano Malattie EMatologiche dell'Adulto Not yet recruiting
Source: - Category: Research Source Type: clinical trials
nez C, Hernández-Cruz A, Dobrovinskaya O Abstract Estrogens demonstrate biological activity in numerous organ systems, including the immune system, and exert their effects through estrogen receptors (ER) of two types: intracellular ERα and ERβ that activate transcriptional factors and membrane G protein-coupled ER GPER. The latter is capable to mediate fast activation of cytosolic signaling pathways, influencing transcriptional events in response to estrogens. Tamoxifen (TAM), widely used in chemotherapy of ERα-positive breast cancer, is considered as an ERα antagonist and GPER agonis...
Source: Journal of Leukocyte Biology - Category: Hematology Authors: Tags: J Leukoc Biol Source Type: research
Source: ClinicoEconomics and Outcomes Research - Category: Health Management Tags: ClinicoEconomics and Outcomes Research Source Type: research
AbstractHomoharringtonine (HHT), a plant alkaloid fromCephalotaxus harringtonia, exhibits a unique anticancer mechanism and has been widely used in China to treat patients with acute myeloid leukemia (AML) since the 1970s. Trial SCMC-AML-2009 presented herein was a randomized clinical study designed based on our previous findings that pediatric AML patients younger than two years old may benefit from HHT-containing chemotherapy regimens. Patients randomized to arm A were treated with a standard chemotherapy regimen comprising mainly of anthracyclines and cytarabine (Ara-C), whereas patients in arm B were treated with HHT-c...
Source: Frontiers of Medicine - Category: General Medicine Source Type: research
This study shows the action of pharmacogenetic variants in NUDT15 in a context of protein structure, which might open novel directions in personalized chemotherapy.Graphical abstract
Source: Biochimica et Biophysica Acta (BBA) Proteins and Proteomics - Category: Biochemistry Source Type: research
AbstractThe aim of this study is to investigate the efficacy and safety of nilotinib combined with multi-agent chemotherapy in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Thirty patients with Ph+ ALL were recruited. Standard induction chemotherapy was given for 4  weeks. Nilotinib was administered beginning on day 15 of induction. After achieving hematologic complete remission (HCR), patients received either seven courses of consolidation or hematopoietic cell transplantation (HCT). Nilotinib was continued 2 years after achieving HCR or before stem cell tr ansplantatio...
Source: Annals of Hematology - Category: Hematology Source Type: research
More News: Chemotherapy | Girls | Health | Leukemia